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Abstract: 3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) is a virucidal 
heterocyclic compound active against various viruses, including HCV, HIV, and simian 
immunodeficiency virus. Using facile synthetic approaches that we developed for the synthesis of 
pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic derivatives, the parallel structural 
optimizations of the central 1,3-thiazin-2-imine core, the benzene part, and the cyclic amidine part of 
PD 404182 were investigated. Replacement of the 6-6-6 pyrimido[1,2-c][1,3]benzothiazin-6-imine 
framework with 5-6-6 or 6-6-5 derivatives led to a significant loss of anti-HIV activity, and 
introduction of a hydrophobic group at the 9- or 10-positions improved the potency. In addition, we 






Since azidothymidine (AZT), a nucleoside reverse transcriptase inhibitor (NRTI), was 
approved for the treatment of HIV infections, a number of anti-HIV drugs have been launched. For 
example, saquinavir and nevirapine were the first protease inhibitor and non-nucleoside reverse 
transcriptase inhibitor (NNRTI), respectively.1 Highly active antiretroviral therapy (HAART) using a 
combination of these antiretrovirals is a standard treatment regimen for HIV infections. The HAART 
regimen significantly reduces viral load in infected patients, leading to significant therapeutic gains 
and reductions in morbidity and mortality.2 However, long-term administration of multiple 
antiretrovirals to maintain life-long latent infection triggers the emergence of drug-resistant variants3 
and drug-related adverse effects.4 For example, high-level viral resistance to NRTI such as AZT, 
stavudine, and didanosine is conferred by mutations frequently observed in patients with virologic 
failure on an NRTI-containing regimen.5 In addition, lipodystrophy and metabolic disorders are often 
observed in patients receiving HIV protease inhibitors.6 To overcome these problems, several 
antiretrovirals with new mechanisms of action have been developed in this decade. A peptide-based 
fusion inhibitor (enfuvirtide),7 an integrase inhibitor (raltegravir),8 and a CC chemokine receptor type 
5 (CCR5) antagonist (maraviroc)9 are examples of new molecular entities used as anti-HIV agents.   
Recently, highly potent small-molecule anti-HIV agents have been reported, which bind to 
viral envelope proteins (Figure 1). 2-Thioxo-1,3-thiazolidine derivative 1 shows potent inhibition of 
HIV-1 replication at nanomolar levels,10 which are directed at the deep hydrophobic pocket in the 
N-terminal heptad repeat trimer of the viral gp41. Compound 1 blocks HIV-1-mediated cell–cell 
fusion and the formation of gp41 six-helix bundles, as does enfuvirtide.10b The bisindole derivative 2 
also exhibits submicromolar inhibition of HIV-1 replication by interaction with the gp41 
hydrophobic pocket in which compound 1 binds.11 Small-molecule CD4 mimics with oxalamide and 
related substructures are another series of anti-HIV agents.12 The representative BMS-448043 (3) 
exhibits subnanomolar anti-HIV activity by interaction with the CD4 binding pocket in gp120.12d 
These small-molecule entry inhibitors with potential oral bioavailability will provide alternative 
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combination regimen(s) of anti-HIV agents for the treatment of drug-resistant variants.  
In our efforts to develop novel anti-HIV compounds,13 we have carried out the random 
screening of small molecules using multinuclear activation of a galactosidase indicator (MAGI) 
assay, in which the inhibitory activity of early-stage HIV infection, including virus attachment and 
membrane fusion to host cells, is evaluated. Among more than 30,000 compounds screened, 
3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine 4 (PD 404182) was identified as a 
potent anti-HIV agent lead (Figure 1). Compound 4 was reported to be an enzyme inhibitor against 
3-deoxy-D-manno-octulosonic acid 8-phosphate synthase14 and phosphopantetheinyl transferase,15 
exerting antimicrobial effects. In the course of our SAR investigations in this study, antiviral 
activities of 4 against HCV, HIV, and simian immunodeficiency virus were reported.16,17 Although 
compound 4 exhibits virucidal effects at high concentrations, the mechanism of action and the target 
molecule remain ambiguous.17 
Recently, we have established two independent approaches for the synthesis of PD 404182 
derivatives (Scheme 1): C–H functionalization of 2-phenyl-1,4,5,6-tetrahydropyrimidine with water 
or t-butylcarbamate in the presence of copper(II) acetate provides pyrimido[1,2-c][1,3]benzoxazine 
or pyrimido[1,2-c]quinazoline in one or two step(s) (Eq. 1, Scheme 1).18 Alternatively, addition of 
2-(2-halophenyl)-1,4,5,6-tetrahydropyrimidine to carbon disulfide, isocyanate, or isothiocyanate, and 
subsequent aromatic nucleophilic substitution (SNAr) affords pyrimidobenzothiazines and -oxazines, 
and pyrimidoquinazolines (Eq. 2, Scheme 1).19 The derivatives obtained from these reactions were 
easily converted to the pyrimido[1,2-c][1,3]benzothiazin-6-imine scaffold. Our two synthetic 
methods provide a variety of PD 404182 derivatives from the corresponding benzaldehydes in a few 
steps and in good yields, facilitating the lead optimization process.20 In this article, a SAR study of 




Results and discussion  
Strategy for the SAR study of PD 404182  
PD 404182 consists of three components, namely a 1,3-thiazin-2-imine core, and left-fused 
benzene and cyclic amidine moieties (Figure 2). In order to obtain detailed insights into the 
relationships between the compound structure and anti-HIV activity, we planned to investigate 
substituent effects on each component: (I) derivatives with various heteroatom (N, S, and O) 
arrangements on the 1,3-thiazin-2-imine core (Figure 2); (II) pyrimido[1,2-c][1,3]thiazin-6-imine 
derivatives fused with a substituted benzene ring or a five- or six-membered aromatic heterocycle; 
and (III) benzo[e][1,3]thiazin-2-imine derivatives fused with a cyclic amidine ring with or without 
accessory alkyl or aryl groups.  
 
Synthesis of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles  
Our investigation began with the synthesis of tricyclic heterocycles with different combinations 
of heteroatoms on the 1,3-thiazin-2-imine core. Previously, we reported syntheses of 
pyrimido[1,2-c][1,3]benzoxazine and pyrimido[1,2-c]quinazoline derivatives using 
copper(II)-mediated C–H functionalization;18 this facilitates the introduction of oxygen or nitrogen 
functional groups at the ortho-position of 2-phenyl-1,4,5,6-tetrahydropyrimidine (5). Using 
compound 5 as a key starting material, a divergent approach was used for the preparation of a series 
of scaffolds (Scheme 2).  
A one-pot reaction for Cu(OAc)2-mediated C–H functionalization of 5 and subsequent 
treatment with triphosgene provided a 1,3-oxazin-2-one derivative 7 (Scheme 2). The same one-pot 
procedure using thiophosgene produced a trace amount of the desired thiocarbonyl derivative 8; 
treatment of the purified intermediate 6 with thiophosgene provided the desired 1,3-oxazin-2-thione 
8 in high yield. 1,3-Oxazin-2-imine 9 was obtained by the reaction of 6 with BrCN.  
The copper-mediated C–N bond formation of compound 5 with tert-butylcarbamate followed 
by spontaneous intramolecular cyclization afforded a pyrimido[1,2-c]quinazolin-6-one scaffold 10, 
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as demonstrated in our previous report (Scheme 2).18 Subsequent treatment with Lawesson’s reagent 
led to formation of the thiocarbonyl derivative 11. Since no hydrolysis of the carbonyl or 
thiocarbonyl group of compound 10 or 11 for construction of the 2-aminoquinazoline structure in 12 
occurred, an alternative approach starting from 2-aminobenzyl alcohol 15 was used for the synthesis 
of the 2-aminoquinazoline derivative 12 (Scheme 3). After protection and PCC oxidation of 15, 
oxidative amidination21 provided 2-(p-tosylamino)phenyltetrahydropyrimidine 17. Deprotection 
followed by BrCN-mediated cyclization of 17 provided the expected 2-aminoquinazoline derivative 
12.  
For the synthesis of pyrimido[1,2-c][1,3]benzothiazine derivatives, we adapted the C–H 
functionalization reaction for C–S bond formation (Scheme 2). After optimization of the reaction 
conditions, we found that exposure of compound 5 to CS2 in the presence of Cu(OAc)2 directly 
afforded a pyrimido[1,2-c][1,3]benzothiazine-6-thione scaffold 13. Hydrolysis of the thiocarbonyl 
group in 13 followed by treatment with BrCN or triphosgene provided 6-imino or 6-oxo derivatives 
(4 or 14), respectively.  
 
Synthesis of pyrimido[1,2-c][1,3]thiazine derivatives with fused benzene and heterocycles  
Pyrimido[1,2-c][1,3]thiazin-6-imine derivatives 28–30 with a series of fused ring systems were 
prepared by consecutive heterocumulene addition and SNAr reactions (Scheme 4).19 These reactions 
provide easy access to the construction of the 1,3-thiazin-2-imine derivatives and are more efficient 
than the diversity-oriented C–H functionalization approach. The oxidative amidination of aromatic 
aldehydes 18–20 with an accessory functional group afforded the corresponding 
2-phenyltetrahydropyrimidine derivatives 21–23. The pyrimido[1,2-c][1,3]thiazine-6-thione scaffold 
24 was obtained by additions of 21f,g,i or 23s,t,u to carbon disulfide followed by SNAr-type C–S 
bond formation. The desired 6-imino derivatives 28f,g,i and 30s,t,u were obtained via hydrolysis of 
the thiocarbonyl group of 24 followed by BrCN treatment. Alternatively, reactions of other 
2-phenyltetrahydropyrimidines 21–23 with tert-butyl isothiocyanate afforded N-(t-Bu)-protected 
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thiazinimine derivatives 25–27, which were treated with TFA to provide the expected products 
28–30. 
The intermediates 25e, 25k, and 26k were subjected to further manipulations to obtain the 
functionalized derivatives (Scheme 5). The nitro group of 25e was reduced by hydrogenation to form 
the 9-amino derivative 31. Alkylation of 31 afforded the 9-(N-methylamino) derivative 25b (Eq. 1, 
Scheme 5). The 9-acetamide derivative 25c was obtained by treatment of 31 with acetic anhydride 
(Eq. 2, Scheme 5). Sandmeyer reaction of 31 gave the 9-azide derivative 25p (Eq. 3, Scheme 5). 
Me2N- and MeO-substituted derivatives (25a, 26a, and 26f) were obtained by Me2NH-mediated 
N-arylation22 of the 9-bromo 25k and 10-bromo derivatives 26k, and NaOMe-mediated Ullmann 
coupling23 of 26k, respectively (Eq. 4 and 7, Scheme 5). The 9-acetyl derivative 25d was obtained by 
Heck reaction24 of 25k with 2-hydroxyethyl vinyl ether (Eq. 5, Scheme 5). Other derivatives with a 
variety of functional groups (25h,l-o,q and 26l,m,q) were synthesized by Suzuki–Miyaura coupling 
reactions25 of 25k and 26k with boronic acids or their pinacol esters (Eq. 6 and 7, Scheme 5). Final 
deprotection of the tert-butyl group in 25 and 26 afforded the 9- or 10-substituted 
pyrimido[1,2-c][1,3]benzothiazine derivatives 28 and 29, respectively.  
 
Synthesis of benzo[e][1,3]thiazine derivatives with fused cyclic amidines  
Benzo[e][1,3]thiazine derivatives with various ring-sized and/or modified cyclic amidine 
moieties 35 were also synthesized by the consecutive heterocumulene addition and SNAr reactions 
(Scheme 6). Oxidative amidination using several diamines 32 proceeded efficiently to form five- or 
six-membered rings (33a–d). The same reaction for the seven-membered amidine (33e) was 
incomplete, but purification of the Boc-protected amidine 36 followed by subsequent deprotection of 
the Boc group gave the pure seven-membered amidine 33e. The resulting amidines were converted to 
cyclic-amidine-fused benzo[e][1,3]thiazin-2-imines 34 via tert-butyl isothiocyanate addition and an 




Structure-activity relationships of the central heterocyclic core in 
pyrimido[1,2-c][1,3]benzothiazines  
Initially, the structural requirements of the 1,3-thiazin-2-imine core substructure in 4 (PD 
404182) for anti-HIV activity were investigated (Table 1). The antiviral activities against the 
HIV-1IIIB strain were evaluated using the MAGI assay. Substitution of the imino group in 4 with a 
carbonyl group (14) resulted in a significant decrease in anti-HIV activity (EC50 = 8.94 M). 
Pyrimido[1,2-c][1,3]benzoxazines (7–9), pyrimido[1,2-c]quinazolines (10–12), and 
pyrimido[1,2-c][1,3]benzothiazine-6-thione (13), in which the 1-sulfur and/or 2-imino groups in 4 
were modified, showed no activity. These results suggested that both the 1-sulfur atom and the 
2-imino group are indispensable functional groups for the inhibitory activity against HIV infection, 
and may be involved in potential interactions with the target molecules.  
 
Structure-activity relationships of the benzene substructure in 
pyrimido[1,2-c][1,3]benzothiazine  
A series of derivatives with modification of the benzene substructure in the 
pyrimido[1,2-c][1,3]benzothiazine were evaluated for anti-HIV activity (Table 2). The addition of 
positively charged N,N-dimethylamino (28a) and N-methylamino groups (28b) at the 9-position 
significantly decreased the anti-HIV activity. The 9-acetamide group (28c), which has 
hydrogen-bond donor/acceptor abilities, also attenuated the bioactivity. The acetyl (28d) and nitro 
(28e) groups, with hydrogen acceptor properties, induced slight decreases in the anti-HIV activity. In 
contrast, derivatives with less-polarized substituents (28f–o and 28q) at this position generally 
reproduced the potent anti-HIV activity of 4. In terms of the electron-donating or -withdrawing 
properties of the substituent groups on the benzene substructure, good correlations were not observed. 
For example, the electron-donating methoxy (28f), methyl (28g), and n-butyl groups (28h), and the 
electron-withdrawing fluoro (28i) and trifluoromethyl groups (28j) exhibited similar anti-HIV 
activities (EC50 = 0.44 – 0.57 M), indicating that the antiviral activity is independent of the 
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electronic state of the 1,3-benzothiazin-2-imine core in forming potential -stacking interaction(s) 
with the target molecules. Among the hydrophobic substituents at this position, bromo (28k), phenyl 
(28l), vinyl (28m), styryl (28n), and pentenyl groups (28o) induced inhibitory activity two or three 
times greater than that of 4 (EC50 = 0.18 – 0.25 M). Modification with photoreactive azido (28p) 
and benzoylphenyl groups (28q) maintained the inhibitory activity; these could be used as probe 
molecules to identify the target molecule(s) of 4.26  
Similar SARs were observed for modification at the 10-position of 
pyrimido[1,2-c][1,3]benzothiazine. Addition of positively charged N,N-dimethylamino (29a) and 
polarized nitro groups (29e) reduced the anti-HIV activity (EC50 = 2.12 and 3.00 M, respectively). 
Hydrophobic groups including methoxy (29f), methyl (29g), bromo (29k), phenyl (29l), vinyl (29m), 
and 4-benzoylphenyl (29q) (EC50 = 0.24 – 0.67 M) had favorable effects on the bioactivity, 
suggesting potential hydrophobic interactions of these additional functional groups with the target 
molecule(s). 
Further miscellaneous modifications of benzothiazine substructure were also investigated 
(Table 2). The naphtho[2,3-e][1,3]thiazine derivative 30r, with a 9,10-fused benzene, exhibited 
anti-HIV activity equipotent to that of the parent 4 (EC50 = 0.56 M). A 6-fold decrease in the 
anti-HIV activity of the pyridine-fused pyrido[3,2-e][1,3]thiazine derivative (30s) was observed 
(EC50 = 2.55 M). In addition, introduction of 8-bromo (30k) and 8,9-fused benzene (30t, 
naphtho[2,1-e][1,3]thiazine) substituents on benzothiazine resulted in a loss of activity, suggesting 
that modification at the 8-position was inappropriate for favorable interactions with the target 
molecule(s). The 11-fluoro derivative 30i and thiophene-fused 30u, which has a 5-6-6 framework 
(thieno[2,3-e][1,3]thiazine), exhibited four times lower and no inhibitory potencies, respectively.  
 
Structure-activity relationships of cyclic amidine part of pyrimido[1,2-c][1,3]benzothiazine  
A SAR study of the top-right cyclic amidine substructure was carried out. The five-membered 
dihydroimidazole derivative 35a had no anti-HIV activity (Table 3), suggesting that the 
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five-membered ring may impair the critical interactions with the target molecule(s) via its 
small-sized ring strain or indirect effects on the thiazinimine core with a possibly altered 
conformation. Similarly, compound 35b with the phenyl-fused dihydropyrimidine substructure 
showed lower inhibitory activity (EC50 = 3.78 M). Appending one or two methyl groups on the 
six-membered pyrimidine (35c and 35d) induced 1.5- to 2-fold higher inhibitory potencies (EC50 = 
0.35 and 0.24 M, respectively) compared with that of the parent compound 4. In addition, 
compound 35e with a seven-membered tetrahydro-1,3-diazepine substructure exhibited similar 
anti-HIV activity to that of 4 (EC50 = 0.31 M).  
 
Mechanistic studies of anti-HIV pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic 
heterocycles  
To investigate the mechanism of action of PD 404182 derivatives, a time of drug addition 
study was carried out (Figure 3). In this experiment, the anti-HIV activity profiles of 427 and its 
derivatives 29k27 were compared with those of well-known anti-HIV agents such as an adsorption 
inhibitor (DS 5000),28 fusion inhibitor [enfuvirtide (T-20)],5 NRTI (AZT),29 NNRTI (nevirapine),30 
and integrase inhibitor (raltegravir).6 After inoculation of HeLa-CD4/CCR5-LTR/β-gal cells with 
HIV-1IIIB, each anti-HIV-1 drug was added at a 90% inhibitory effect concentration at the indicated 
time points. The inhibitory effects on the infection were determined by counting the blue cells 48 h 
later. This investigation revealed that compound 4 (PD 404182) had an inhibitory profile in the early 
stage of viral infection similar to those of DS 5000 and enfuvirtide (Figure 3). Identical profiles were 
observed for derivative 29k.  
To gain additional insights into the mechanism of action of PD 404182 derivatives, the 
antiviral activities against other HIV subtypes were evaluated (Table 4). Compound 4 was effective 
against not only HIV-1IIIB but also other two HIV-1 strains (HIV-1NL4-3 and HIV-1BaL) with similar 
potency. Both HIV-1IIIB and HIV-1NL4-3 strains utilize CXCR4 as a coreceptor for entry, while 
HIV-1BaL strain does CCR5, indicating that chemokine receptors CXCR4 and CCR5 are not the 
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molecular targets of PD 404182 derivatives. The similar level of antiviral activity of 4 against HIV-2 
(HIV-2EHO and HIV-2ROD), which is mainly distributed in West Africa, was observed. Highly potent 
inhibitory activities of a derivative 35d27 against these HIV strains were observed, as in the case of 
the SAR study of the HIV-1IIIB strain discussed above. It has been well known that NNRTIs are not 
effective against HIV-2, highlighting that PD 404182 derivatives do not act as NNRTIs. Although PD 
404182 derivatives and enfuvirtide showed similar anti-HIV-1 profile in the time of drug addition 
assay, HIV-2EHO and HIV-2ROD infection were affected by PD 404182 derivatives, in contrast with 
the less effective enfuvirtide,31 suggesting that PD 404182 derivatives may not be directed at the HIV 
gp41 envelope protein. Recent reports have suggested that the antiviral activities of compound 4 
against HIV, HCV, and pseudotype lentiviruses were derived from disruption of the structural 
integrities of virions.17 Although the mechanism of action of PD 404182 derivatives is not fully 
understood at this stage, the unidentified biomolecule(s) in viruses or host cells, including envelope 
protein(s), lipid membranes and/or sugar chain(s), could be promising molecular targets for this new 
class of anti-HIV agents.  
 
Conclusion 
In conclusion, we have designed and synthesized PD 404182 derivatives for a novel series of 
anti-HIV agents. Comprehensive SAR studies demonstrated that the 6-6-6 fused 
pyrimido[1,2-c][1,3]benzothiazine scaffold and the heteroatom arrangement in the thiazinimine 
moiety are indispensable for the inhibitory activity of 4 (PD 404182) against HIV infection. 
Optimization studies of the benzene and cyclic amidine rings indicate that the introduction of a 
hydrophobic group on the benzene ring and the amidine group is more effective in improving the 
antiviral activity, giving potential favorable interaction(s) with the target molecule(s). In addition, PD 
404182 derivatives could be promising agents for treatment of HIV-2 infection. We also revealed, 
using time of drug addition experiments, that PD 404182 derivatives prevent the HIV infection 
process at an early stage. For iterative molecular design of more effective derivatives based on 
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binding modes, the identification of the target molecule(s) of PD 404182 derivatives is being 




1H NMR spectra were recorded using a JEOL AL-400 or a JEOL ECA-500 spectrometer. 
Chemical shifts are reported in δ (ppm) relative to Me4Si as an internal standard. 13C NMR spectra 
were referenced to the residual solvent signal. Exact mass (HRMS) spectra were recorded on a 
JMS-HX/HX 110A mass spectrometer. Melting points were measured by a hot stage melting point 
apparatus (uncorrected). For flash chromatography, Wakogel C-300E (Wako) or aluminium oxide 90 
standardized (Merck) were employed. For preparative TLC, TLC Silica gel 60 F254 (Merck), TLC 
Aluminium oxide 60 F254 basic (Merck), or NH2 Silica Gel 60 F254 Plate (Wako) were employed. For 
analytical HPLC, a Cosmosil 5C18-ARII column (4.6 × 250 mm, Nacalai Tesque, Inc., Kyoto, 
Japan) was employed with method A [a linear gradient of CH3CN containing 0.1% (v/v) TFA] or 
method B [a linear gradient of CH3CN containing 0.1% (v/v) NH3] at a flow rate of 1 cm3 min-1 on a 
Shimadzu LC-10ADvp (Shimadzu Corp., Ltd., Kyoto, Japan), and eluting products were detected by 
UV at 254 nm. The purity of the compounds was determined by combustion analysis or HPLC 
analysis as >95% unless otherwise stated. 
 
General procedure of oxidative amidination: synthesis of 
2-(3-bromo-2-fluorophenyl)-1,4,5,6-tetrahydropyrimidine (23k). To a solution of 
3-bromo-2-fluorobenzaldehyde 20k (0.71 g, 3.5 mmol) in t-BuOH (33 cm3) was added 
propylenediamine (285.4 mg, 3.9 mmol). The mixture was stirred at 70 °C for 30 min, and then 
K2CO3 (1.45 g, 10.5 mmol) and I2 (1.11 g, 4.4 mmol) were added. After being stirred at same 
temperature for 3 h, the mixture was quenched with sat. Na2SO3. The organic layer was separated 
and concentrated. The resulting solid was dissolved in H2O, and then pH was adjusted to 12–14 with 
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2N NaOH. The whole was extracted with CHCl3. The extract was dried over MgSO4. After 
concentration, the resulting solid was recrystallized from CHCl3–n-hexane to give compound 23k as 
colorless crystals (0.62 g, 69%): mp 99 °C; IR (neat)max/cm-1: 1624 (C=N); δH (400 MHz; CDCl3; 
Me4Si) 1.84-1.89 (2H, m, CH2), 3.50 (4H, t, J = 5.7 Hz, 2 × CH2), 5.13 (1H, br s, NH), 7.03 (1H, td, 
J = 8.0, 0.9 Hz, Ar), 7.54 (1H, ddd, J = 8.0, 6.4, 1.3 Hz, Ar) and 7.69 (1H, ddd, J = 8.0, 6.5, 1.3 Hz, 
Ar). δC (100 MHz; CDCl3) 20.6, 42.1 (2C), 109.6 (d, J = 22.3 Hz), 125.1 (d, J = 4.1 Hz), 126.3 (d, J 
= 13.2 Hz), 129.8 (d, J = 3.3 Hz), 134.3, 150.8 and 156.3 (d, J = 248.3 Hz); δF (500 MHz; CDCl3) 
–110.7; Anal. Calc. for C10H10BrFN2: C, 46.72; H, 3.92; N, 10.90. Found: C, 46.64; H, 4.10; N, 
10.93. 
 
General procedure of CS2-mediated cyclization for 
pyrimido[1,2-c][1,3]benzothiazine-6-thiones 24: synthesis of 
3,4-dihydro-2H,6H-pyrimido[1,2-c]thieno[2,3-e][1,3]thiazin-6-thione (24u). To a mixture of 
2-(3-bromothiophen-2-yl)-1,4,5,6-tetrahydropyrimidine 23u (122.6 mg, 0.50 mmol) and NaH (40.0 
mg, 1.0 mmol; 60% oil suspension) in DMF (1.7 cm3) was added CS2 (0.060 cm3, 1.0 mmol) under 
an Ar atmosphere. After being stirred at 80 °C for 12 h, the mixture was concentrated. The residue 
was purified by flash chromatography over silica gel with n-hexane–EtOAc (8:2) to give the 
compound 24u as pale yellow solid (80.5 mg, 67%): mp 167 °C (from CHCl3–n-hexane); IR 
(neat)max/cm-1: 1624 (C=N); δH (400 MHz; CDCl3; Me4Si) 2.04-2.10 (2H, m, CH2), 3.68 (2H, t, J = 
5.5 Hz, CH2), 4.42 (2H, t, J = 6.1 Hz, CH2), 6.76 (1H, d, J = 5.4 Hz, Ar) and 7.49 (1H, d, J = 5.4 Hz, 
Ar). δC (100 MHz; CDCl3) 21.5, 45.0, 48.5, 122.3, 128.4, 130.8, 131.0, 141.7 and 189.7; HRMS 
(FAB): m/z Calc. for C9H9N2S3 [M + H]+ 240.9928; found: 240.9936. 
 
General procedure of t-BuNCS-mediated cyclization for t-Bu protected 
pyrimido[1,2-c][1,3]thiazin-6-imines 25–27, and 34: synthesis of 
N-tert-Butyl-3,4-dihydro-9-nitro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (25e). To a 
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mixture of 2-(2-fluoro-4-nitrophenyl)-1,4,5,6-tetrahydropyrimidine 21e (2.0 g, 8.96 mmol) and NaH 
(716.8 mg, 17.92 mmol; 60% oil suspension) in DMF (29.8 cm3) was added t-BuNCS (2.28 cm3, 
17.92 mmol) under an Ar atmosphere. After being stirred at -20 °C to rt for 2 days, EtOAc was added. 
The resulting solution was washed with sat. NaHCO3, brine, and dried over MgSO4. After 
concentration. the residue was purified by flash chromatography over aluminum oxide with 
n-hexane–EtOAc (10:0 to 9:1) to give compound 25e as pale yellow solid (1.77 g, 62%): mp 
152–153 °C (from CHCl3–n-hexane); IR (neat)max/cm-1: 1604 (C=N), 1591 (NO2), 1581 (C=N), 
1523 (NO2); δH (500 MHz; CDCl3; Me4Si) 1.39 (9H, s, 3 × CH3), 1.91-1.96 (2H, m, CH2), 3.66 (2H, 
t, J = 5.2 Hz, CH2), 3.88 (2H, t, J = 5.7 Hz, CH2), 7.97 (2H, dd, J = 9.7, 2.3 Hz, Ar), 8.01 (2H, d, J = 
2.3 Hz, Ar) and 8.39 (1H, d, J = 9.2 Hz, Ar). δC (125 MHz; CDCl3) 21.7, 30.0, 45.3, 45.5, 54.5, 119.9, 
120.3, 130.0, 131.1, 132.8, 136.1, 146.5 and 148.5; HRMS (FAB): m/z Calc. for C15H19N4O2S [M + 
H]+ 319.1229; found: 319.1229.  
 
General procedure of BrCN-mediated cyclization for pyrimido[1,2-c][1,3]thiazin-6-imines 
28 and 30: synthesis of 3,4-dihydro-9-methyl-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine 
(28g). 3,4-Dihydro-9-methyl-2H-pyrimido[1,2-c][1,3]benzothiazine-6-thione 24g (62.1 mg, 0.25 
mmol) was suspended into a 0.1M solution of NaOH in MeOH/H2O (9:1) (5 cm3). After being stirred 
for 12 h under reflux, the mixture was concentrated. The residue was suspended in anhydrous EtOH 
(1 cm3) and BrCN (53.0 mg, 0.50 mmol) was added under Ar atmosphere. After stirring for 2 h under 
reflux, the reaction mixture was quenched with 2N NaOH. The whole was extracted with CHCl3, and 
dried over MgSO4. After concentration, the residue was purified by flash chromatography over 
aluminum oxide with n-hexane–EtOAc (9:1) to give the compound 28g as colorless solid (39.2 mg, 
68%): mp 121 °C (from CHCl3–n-hexane); IR (neat)max/cm-1: 1620 (C=N), 1569 (C=N); δH (500 
MHz; CDCl3; Me4Si) 1.94-1.99 (2H, m, CH2), 2.32 (3H, s, CH3), 3.67 (2H, t, J = 5.7 Hz, CH2), 4.01 
(2H, t, J = 6.3 Hz, CH2), 6.84 (1H, s, Ar), 7.02 (1H, d, J = 8.6 Hz, Ar), 7.16 (1H, br s, NH) and 8.10 
(1H, d, J = 8.6 Hz, Ar). δC (125 MHz; CDCl3) 21.1, 21.1, 43.8, 44.9, 123.6, 124.1, 127.4, 128.6, 
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128.8, 141.1, 146.6 and 153.6; HRMS (FAB): m/z Calc. for C12H14N3S [M + H]+ 232.0908; found: 
232.0912.  
 
General procedure of tert-butyl deprotection for 
pyrimido[1,2-c][1,3]benzothiazin-6-imines 28-30: synthesis of 
3,4-dihydro-9-nitro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (28e). TFA (1.5 cm3) was 
added to a mixture of N-(tert-butyl)-3,4-dihydro-9-nitro-2H, 
pyrimido[1,2-c][1,3]benzothiazin-6-imine 25e (47.8 mg, 0.15 mmol) in CHCl3 and molecular sieves 
4Å (225 mg, powder, activated by heating with Bunsen burner). After being stirred under reflux for 
1.5 h, the mixture was concentrated. To a mixture of this residue in CHCl3 was added dropwise Et3N 
at 0 °C to adjust pH to 8–9. The whole was extracted with EtOAc, and the extract was washed with 
sat. NaHCO3, brine, and dried over MgSO4. After concentration, the residue was purified by flash 
chromatography over aluminum oxide with n-hexane–EtOAc (19:1 to 1:1) to give compound 28e as 
pale yellow solid (24.9 mg, 63%): mp 170–172 °C (from CHCl3–n-hexane); IR (neat)max/cm-1: 
1620 (C=N), 1587 (NO2), 1568 (C=N), 1523 (NO2); δH (400 MHz; CDCl3; Me4Si) 1.97-2.03 (2H, m, 
CH2), 3.74 (2H, t, J = 5.6 Hz, CH2), 4.04 (2H, t, J = 6.2 Hz, CH2), 7.41 (1H, br s, NH), 7.93 (1H, d, J 
= 2.2 Hz, Ar), 8.00 (1H, dd, J = 9.0, 2.2 Hz, Ar) and 8.42 (1H, d, J = 9.0 Hz, Ar). δC (100 MHz; 
CDCl3) 20.8, 43.8, 45.2, 118.9, 120.5, 130.4, 130.8, 131.7, 145.1, 148.7 and 151.3; Anal. Calc. for 
C11H10N4O2S: C, 50.37; H, 3.84; N, 21.36. Found: C, 50.29; H, 4.03; N, 21.08.  
 
General procedure of Suzuki-Miyaura cross coupling for 9-aryl 
pyrimido[1,2-c][1,3]thiazine derivatives: synthesis of 
N-tert-butyl-9-phenyl-3,4-dihydro-2H.6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine 25l. To a 
solution of N-(tert-butyl)-3,4-dihydro-9-bromo-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine 
25k (52.8 mg, 0.15 mmol) and phenylboronic acid (21.9 mg, 0.18 mmol) in a mixture of toluene (1.5 
cm3), EtOH (0.9 cm3) and 1M aq. K2CO3 (1.5 cm3) was added Pd(PPh3)4 (6.9 mg, 4 mol%) and 
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PdCl2(dppf)·CH2Cl2 (3.67 mg, 3 mol%). After being stirred at reflux for 1 h, the mixture was 
extracted with CHCl3. The organic layers were dried over MgSO4 and concentrated. The residue was 
purified by flash chromatography over aluminum oxide with n-hexane–EtOAc (10:0 to 9:1) to give 
the compound 25l as colorless solid (44.8 mg, 85%): mp 122.5–124 °C (from CHCl3–n-hexane); IR 
(neat)max/cm-1: 1592 (C=N); δH (500 MHz; CDCl3; Me4Si) 1.40 (9H, s, 3 × CH3), 1.90-1.95 (2H, m, 
CH2), 3.64 (2H, t, J = 5.4 Hz, CH2), 3.89 (2H, t, J = 6.0 Hz, CH2), 7.33-7.37 (2H, m, Ar), 7.41-7.44 
(3H, m, Ar), 7.58 (2H, d, J = 6.9 Hz, Ar) and 8.25 (1H, d, J = 8.6 Hz, Ar). δC (125 MHz; CDCl3) 21.9, 
30.0 (3C), 45.1, 45.4, 54.2, 122.7, 124.8, 126.5, 127.0 (2C), 128.0, 128.8 (2C), 128.9, 129.5, 138.3, 
139.4, 142.9 and 147.7; HRMS (FAB): m/z Calc. for C21H24N3S [M + H]+ 350.1691; found: 
350.1683. 
  
Determination of anti-HIV activity 
The sensitivity of three HIV-1 strains and two HIV-2 strains was determined by the MAGI 
assay.32 The target cells (HeLa-CD4/CCR5-LTR/β-gal; 104 cells/well) were plated in 96-well flat 
microtiter culture plates. On the following day, the cells were inoculated with the HIV-1 (60 MAGI 
U/well, giving 60 blue cells after 48 h of incubation) and cultured in the presence of various 
concentrations of the drugs in fresh medium. Forty-eight hours after viral exposure, all the blue cells 
strained with X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) were counted in each well. 
The activity of test compounds was determined as the concentration that blocked HIV-1 infection by 
50% (50% effective concentration [EC50]). EC50 was determined by using the following formula:  
EC50 = 10^[log(A/B)×(50 – C)/(D – C) + log(B)],  
wherein 
A: of the two points on the graph which bracket 50% inhibition, the higher concentration of the 
test compound,  
B: of the two points on the graph which bracket 50% inhibition, the lower concentration of the 
test compound,   
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C: inhibitory activity (%) at the concentration B,  
D: inhibitory activity (%) at the concentration A.  
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Figure 1. Structures of newly reported anti-HIV compounds (1–3) targeting HIV-1 envelope 
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Scheme 2. Synthesis of PD 404182 derivatives with different combinations of heteroatoms. Reagents 
and conditions: (a) Cu(OAc)2, H2O, O2, DMF, 130 °C, 69%; (b) triphosgene, TMEDA, CH2Cl2, 0 °C 
to rt, 70% [2 steps (a,b)]; (c) thiophosgene, Et3N, CH2Cl2, 0 °C to rt, quant.; (d) BrCN, CH2Cl2, rt, 
34%; (e) Cu(OAc)2, BocNH2, O2, DMF, 130 °C, 53%; (f) Lawesson’s reagent, xylene, reflux, 19%; 
(g) Cu(OAc)2, CS2, O2, 1,4-dioxane, 130 °C, 11%; (h) NaOH, MeOH, H2O, reflux; (i) BrCN, EtOH, 





























































Scheme 3. Synthesis of 2-aminoquinazoline derivative 12. Reagents and conditions: (a) p-TsCl, 
pyridine, CHCl3, rt; (b) PCC, silica gel, CH2Cl2, rt, 80% [2 steps (a,b)]; (c) 1,3-propanediamine, I2, 
K2CO3, t-BuOH, 70 °C, 98%; (d) conc. H2SO4, 100 °C, then NaOH, H2O; (e) BrCN, EtOH, reflux, 



















Scheme 4. Synthesis of pyrimido[1,2-c][1,3]thiazin-6-imine derivatives fused with substituted 
benzene and heterocycles (28–30). Reagents and conditions: (a) 1,3-propanediamine, I2, K2CO3, 
t-BuOH, 70 °C, 58-91%; (b) NaH, CS2, DMF, 80 °C, 67%-quant.; (c) NaH or t-BuOK, t-BuNCS, 
DMF or DMAc, -20–80 °C, 28-95%; (d) (i) NaOH, MeOH, H2O, reflux, (ii) BrCN, EtOH, reflux, 








(X = F or Br)
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18 (R1 = H, R2 = accessory group)
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Scheme 5. Synthesis of 9- or 10-substituted 
pyrimido[1,2-c][1,3]benzothiazin-6-imine 
derivatives. Reagents and conditions: (a) H2, 
Pd/C, EtOH, rt, 88%; (b) NaOMe, (CH2O)n, 
MeOH, reflux, then NaBH4, 91%; (c) TFA, 
MS4Å, CHCl3, reflux, 37-95%; (d) Ac2O, 
DMAP, Et3N, CH2Cl2, rt, quant.; (e) NaNO2, 
AcOH, H2O, 0 °C, then NaN3, 70%; (f) 
Pd(OAc)2, t-Bu3P, NHMe2, THF, KOt-Bu, 
toluene, reflux, quant.; (g) 
2-hydroxyethylvinylether, Pd(OAc)2, 
1,3-bis(diphenylphosphino)propane, K2CO3, 
H2O, 90 °C, 13% [2 steps (g,c)]; (h) R-B(OH)2 
or R-Bpin, Pd(PPh3)4, PdCl2(dppf)·CH2Cl2, 
K2CO3, toluene or 1,4-dioxane, EtOH, H2O, 
reflux, 62-96%; (i) n-BuB(OH)2, Pd2(dba)3, 
P(t-Bu)3, CsCO3, 1,4-dioxane, reflux, 6% (for 
25h); (j) Pd(Pt-Bu)2, NHMe2, THF, KOt-Bu, 
toluene, 170 °C, 67% (for 26a); (k) CuBr, 
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Scheme 6. Synthesis of benzo[e][1,3]thiazine derivatives with fused cyclic amidines. Reagents and 
conditions: (a) 2-fluorobenzaldehyde or 2-bromobenzaldehyde, I2, K2CO3, t-BuOH, 70 °C, 68-79%; 
(b) NaH, t-BuNCS, DMF, rt–80 °C, 18-50%; (c) TFA, MS4Å, CHCl3, reflux, 16-86%; (d) Boc2O, 
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a EC50 values were the concentration that blocks HIV-1 infection by 50% and derived from three 
independent experiments.  
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a EC50 values were the concentration that blocks HIV-1 infection by 50% and derived from three 
independent experiments.  
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HIV-1NL4-3 0.38 ± 0.06 0.25 ± 0.03
HIV-1BaL 0.37 ± 0.06 0.16 ± 0.02
HIV-2EHO 0.31 ±0.06 0.17 ± 0.03
HIV-2ROD 0.30 ± 0.06 0.11 ± 0.03
a EC50 values were the concentration that blocks HIV infection by 50% and derived from three 
independent experiments.  
